-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 13, the official website of the 2021 European Society of Medical Oncology (ESMO) annual meeting officially announced the progress of many clinical studies in the form of electronic posters
.
Among them, the report of the bispecific antibody EpCAM/CD3 bi-antibody from Wuhan Youzhiyou Biopharmaceutical is particularly eye-catching
Among them, the report of the bispecific antibody EpCAM/CD3 bi-antibody from Wuhan Youzhiyou Biopharmaceutical is particularly eye-catching
The results of the EpCAM/CD3 double antibody released by Wuhan Youzhiyou are very good, which brings a positive signal to the development of CD3 recruiting double antibody in the field of non-hematological tumors
.
According to the China Drug Clinical Trial Registration and Information Disclosure Platform, Wuhan Youzhiyou EpCAM/CD3 has been led by Director Xu Jianming of Beijing 301 Hospital to carry out Phase II clinical trials.